skip to main content

"Re: Energie für morgen"

Lars Angenent, Professor of Environmental Biotechnology at the University of Tübingen and CMFI Principal Investigator, was interviewed for the ARTE broadcast "Re: Energie für morgen".

11.11.2022 In the Media

In the documentary, Lars Angenent gives an insight into his research work in Tübingen and explains how he uses wind power to convert harmful CO2 from the atmosphere into renewable methane gas that can be fed directly into the gas grid.

The greenhouse gas CO2 produced by humans is considered one of the main causes of climate change. Angenent's innovation contributes to solving this problem. CO2 is used as a building block for methane production using bacteria. His vision of sustainable production of biogas such as methane, is particularly relevant now in the wake of the climate crisis and for supply independence from imported gas.

He says, "If we really want it, we can do it. The technology is ready, but we have to be fast."

You can find the complete broadcast in the ARTE media library.

Under the title "Clever in die Zukunft: Alternativen für die Energiewende", it was also on ZDF's plan b broadcast. Go to ZDF media library (only German)

 

 

Scientific Contact

Prof. Dr. Ir.  Largus  T.  Angenent

University of Tübingen
Zentrum für Angewandte Geowissenschaften
Umweltbiotechnologie

l.angenent@uni-tuebingen.de

Website

Press Contact

Leon Kokkoliadis
Public Relations Management

Tel: +49 7071 29-74707
E-Mail: leon.kokkoliadis@uni-tuebingen.de

 

Related Articles

Power-to-vitamins: microbes produce folate from simple basic ingredients
12.09.2024 Power-to-vitamins: microbes produce folate from simple basic ingredients Press Release
New Podcasts with Hannes Link and Eric Kemen
10.09.2024 New Podcasts with Hannes Link and Eric Kemen CMFI News
CMFI Mediathek Launch
09.09.2024 CMFI Mediathek Launch CMFI News
Nasal microbiome: depriving multi-resistant bugs of iron
05.08.2024 Nasal microbiome: depriving multi-resistant bugs of iron Press Release
Phage lysin compound HY-133: Start of clinical phase I
30.07.2024 Phage lysin compound HY-133: Start of clinical phase I Press Release
Samuel Wagner Elected Vice-President
25.07.2024 Samuel Wagner Elected Vice-President Press Release